drugset / Trial / NCT02204410
Omega-3 Supplementation to ADHD Medication in Children
NaSingle-groupOpen-labelTreatment
Summary
This study is a 12-week open-label trial to assess the effectiveness of Omega-3 fatty acids for deficient emotional self-regulation (DESR) as a supplement to Attention Deficit/Hyperactivity Disorder (ADHD) treatment in children and adolescents with Attention Deficit/Hyperactivity Disorder. Subjects will be between the ages of 6-17 and will currently be on medication for their Attention Deficit/Hyperactivity Disorder but still experience DESR traits.
Timeline
- Start
- 2014-07
- Primary completion
- 2016-05
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omega 3 fatty acid | Other / unclassified | — | — |
| Background | Adderall | Unknown | — | — |
| Background | Amphetamine | Unknown | — | — |
| Background | Dextroamphetamine | Small molecule | — | — |
| Background | Guanfacine | Small molecule | — | — |
| Background | Lisdexamfetamine Dimesylate | Small molecule | — | — |
| Background | Methylphenidate | Small molecule | — | — |
| Background | Stratterra | Unknown | — | — |
| Background | dexmethylphenidate | Unknown | — | — |